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Donald A. Richards, MD, Michael Savin, MD,¶ Robert L. Ruxer, MD,# Craig H. Reynolds, MD,**
Feng Zhan, PhD,** Jane L. Bromund, RN, MSN,†† Ruqin Chen, MS,†† and Coleman Obasaju, MD††
Introduction: We undertook a phase II trial to assess the efficacy
and safety of single-agent pemetrexed (P) in relapsed small-cell lung
cancer (SCLC) patients.
Methods: Patients had limited- or extensive-stage SCLC, perfor-
mance status 0 to 2, and one prior chemotherapy regimen. Initial P
dose was 500 mg/m2 every 21 days. Planned sample sizes were 36
sensitive (S) patients in a two-stage sequential fashion with early
stopping rule, and 25 refractory (R) patients in a single-stage design
without stopping rule. Patients received folic acid and Vitamin B12
prior to P, and B12 could be given up until P treatment. Primary
outcome measure was response rate.
Results: Enrollment occurred from July 2004 to March 2006. The
stopping rule was invoked when3 of 14 S patients responded. The
protocol was amended to evaluate P 900 mg/m2 in cohorts of 40 S
and 40 R patients. Overall, 121 patients were enrolled, with 116
patients treated. S (n  53) and R (n  63) patients were analyzed
separately at both dose levels. Across the 4 treatment groups (S500,
S900, R500, R900), 1 patient (2.63%) in the S900 group had a
partial response. Overall, 18 patients (16%) had stable disease.
Eighty-seven patients (75%) had progressive disease. Responses
were not evaluable in 10 patients (8.6%). Overall response rate was
0.9%. Across treatment groups, disease control rates (partial re-
sponse  stable disease) were 20%, 15.8%, 21.7%, and 12.5%,
respectively. Median time to progression ranged from 1.2 to 1.5
months, median survival times ranged from 2.5 to 6.1 months, and
1-year survival rates ranged from 5.6 to 25.8%. Common grade 3/4
hematologic toxicities (at 500 and 900 mg/m2) were neutropenia
(16%; 9%) and leukopenia (11%; 8%), and nonhematologic toxic-
ities were dyspnea (11%; 10%) and fatigue (16%; 9%). Retrospec-
tive analysis of cycle 1 events by timing of B12 administration
showed no trend toward more frequent serious toxicities when B12
was given 7 days prior to P.
Conclusions: Single-agent P 500 mg/m2 shows minimal activity in
relapsed SCLC patients. P can be given at 900 mg/m2 without
significant increase in serious toxicities, but does not seem to
increase efficacy. B12 given 7 days before P does not seem to be
associated with increased serious toxicities.
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Small-cell lung cancer (SCLC) accounts for about 13% ofall lung cancer diagnoses annually, with approximately
27,700 new cases expected in 2007.1 Although incidence
seems to have declined slightly over the last three decades,
SCLC continues to be a significant public health concern2 and
a clinical challenge, with few effective treatment options.
SCLC is exceptionally responsive to chemotherapy.
Complete response rates of 45 to 75% have been reported in
treated patients with limited-stage disease (LS-SCLC), and 20
to 30% in patients with extensive-stage disease (ES-SCLC).
However, response durations are usually short, with progres-
sion-free survival times of only about 12 months in patients
with LS disease, and 4 months in patients with ES disease.
Relapse is common, and associated with a very poor prog-
nosis. Patients who relapse more than 3 months after first-line
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therapy are commonly called sensitive, while those who relapse
within 3 months of initial treatment are called refractory.3
The current standard second-line chemotherapy for
sensitive patients is topotecan, based on a phase III study
showing better symptom palliation versus the combination of
cyclophosphamide, doxorubicin, and vincristine.4 For pa-
tients who are refractory to first-line therapy, there are no
approved agents. Current practice guidelines support the use
of a number of single-agent and combination regimens to
treat relapsed disease, taking into account performance status,
treatment-free interval, and extent of response to first-line
therapy.5,6 Still, evidence of clinical benefit for any of these
options is limited and the evaluation of new agents is needed.
Pemetrexed (Alimta; Eli Lilly and Company, Indianap-
olis, IN) is a multitargeted antifolate that inhibits thymidylate
synthase, dihydroflate reductase, and glycinamide ribonucle-
otide formyl transferase.7,8 Pemetrexed has shown activity as
a single agent or in combination with a platinum in both
non-small cell lung cancer and malignant pleural mesotheli-
oma.9–16 Folic acid and Vitamin B12 are effective in reducing
pemetrexed-related toxicities17 and are currently required for
toxicity prophylaxis. Given the activity and favorable toxicity
profile of pemetrexed in non-small cell lung cancer, as well as
its ease of administration to outpatients, we undertook a
phase II trial to examine the activity and tolerability of this
novel agent in both sensitive and refractory relapsed SCLC
patients.
PATIENTS AND METHODS
Eligibility Criteria
To be included in the trial, patients were required to
have histologically- or cytologically-confirmed SCLC, fur-
ther classified as either LS or ES disease, and to have
received one prior chemotherapy, immunotherapy, or bio-
logic regimen (with 3 or more weeks elapsed since last
treatment and at least 2 weeks elapsed since any prior
radiation therapy). For this trial, patients with sensitive dis-
ease were defined as those having had a previous response,
but who progressed more than 2 months after the end of their
first-line regimen. Patients with refractory disease were de-
fined as those who progressed while on first-line therapy, or
who had any response but progression within 2 months from
the end of the first-line regimen. Patients had to be 18 years
of age or older, provide written informed consent, and be
compliant with vitamin supplementation and a reliable
method of birth control. Patients were also required to have
an Eastern Cooperative Oncology Group performance status
of 0–2, measurable disease as defined by the Response
Evaluation Criteria in Solid Tumors,18 adequate organ func-
tion and bone marrow reserve and a life expectancy of at least
12 weeks.
Patients who had received investigational treatment
within 30 days of study entry or who had participated in
another pemetrexed trial were excluded. Patients were also
excluded for prior whole pelvis radiation, prior radiation to
more than 25% of the bone marrow, serious concomitant
systemic disorders, second primary malignancies, symptom-
atic central nervous system metastasis, third-space fluid col-
lections not manageable by drainage or other procedures,
pregnancy, breast-feeding, and/or the inability to interrupt
aspirin or nonsteroidal antiinflammatory agents for pem-
etrexed therapy.
The study was conducted at three centers in the United
States. One of the centers enrolled patients via a nationwide
network of investigative sites, under the direction of one
principal investigator. Before initiating the study, each cen-
ter’s ethical review board approved the protocol. The trial
was conducted in compliance with good clinical practice,
federal and institutional guidelines, and the Declaration of
Helsinki.
Study Design and Sample Size
This nonrandomized, open-label phase II trial was de-
signed to enroll 36 sensitive patients in a two-stage sequential
manner. The trial plan specified early stopping if fewer than
3 of 14 qualified sensitive patients failed to respond or had
unacceptable toxicity. There was at least a 44.8% chance of
early termination if the true response rate was less than or
equal to 20% (H0) and no greater than a 4.0% chance if the
true response rate was as high as 40% (Ha). The overall
probabilities of type I and type II errors were 0.083 and
0.111, respectively.
Twenty-five qualified refractory patients were planned
for enrollment in a single-stage fashion without a stopping
rule to assess response rate. While the width of the 95%
confidence interval (CI) for the true response rate would vary
according to the actual observed response rate, responses in 5
of 25 patients would produce an interval of 6.8 to 40.7%.19
Treatment Plan
Eli Lilly and Company (Indianapolis, IN) provided
pemetrexed in lyophilized powder form in 500-mg vials.
Vials were reconstituted with sodium chloride and then fur-
ther diluted to produce a final solution for intravenous infu-
sion. Patients received pemetrexed 500 mg/m2 intravenously
over 10 minutes on day 1 of every 21-day cycle. Pemetrexed
was administered on an outpatient basis at the investigative
site. Treatment continued for six cycles, or until disease
progression. Patients could receive additional cycles if this
was judged to be in their best interest by the treating physi-
cian and the sponsor physician.
All patients received vitamin supplementation and rash
prophylaxis as follows: folic acid 350 to 1000 g orally each
day, beginning 5 to 7 days before the first dose of pemetrexed
and continuing until 3 weeks after the final pemetrexed dose;
Vitamin B12 1000 g intramuscularly 0 to 14 days before the
first pemetrexed dose (it was recommended that Vitamin B12
be given within 7 to 14 days before the first pemetrexed dose,
but administration at any time up until just before the start of
the first infusion was allowed), and repeated every 9 weeks
until 3 weeks after the final pemetrexed dose; dexamethasone
4 mg orally twice daily (or locally available equivalent) on
the day before, day of, and day after each pemetrexed dose
unless clinical contraindications were present. Higher or
additional doses of dexamethasone were permitted for rea-
sons other than routine rash prophylaxis, such as emesis
prophylaxis.
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Patients received full supportive care while on study.
Erythropoietin was allowed. The use of prophylactic granu-
locyte colony-stimulating factor or thrombopoiesis stimula-
tors was not permitted. Patients with an absolute neutrophil
count (ANC) below 0.5  109/liter, neutropenic fever or
documented infections while neutropenic could receive gran-
ulocyte colony-stimulating factor.
Baseline and Treatment Assessments
At baseline and before day 1 of each cycle, patients
underwent physical examination, performance status assess-
ment, and toxicity grading using National Cancer Institute
Common Toxicity Criteria version 2.0.20 Tumor measure-
ments (by radiologic imaging, inspection, and/or palpation)
were performed at baseline and just before every other cycle.
Tumor responses required radiologic confirmation within 4
weeks of initial response. Upon discontinuation of study
therapy, tumor measurements were obtained approximately
every 6 weeks for 6 months, or until disease progression was
documented. Thereafter, tumor measurements were repeated
approximately every 12 weeks as clinically indicated. Chem-
istry assessments were required on days 1 and 8 of each
cycle, and hematology assessments were performed weekly.
Dose Modifications
An ANC 1.5  109/liter, platelet count 100 
109/liter, and calculated creatinine clearance 45 ml/min21
were required before the start of any cycle. Beginning with
cycle 2, dose reductions were made based on nadir neutrophil
and platelet counts from the preceding cycle. Patients with a
platelet nadir 50  109/liter and ANC nadir 0.5 
109/liter received 100% of the prior cycle dose. Patients with
a platelet nadir 25  109/liter (or 50  109/liter with
grade 2 bleeding) and any ANC nadir received 50% of the
prior cycle dose. Patients who developed febrile neutropenia
subsequently received 75% of the prior cycle dose, as did
patients who experienced grade 3 or greater nonhematologic
toxicities (with the exception of transaminase elevations,
nausea, or vomiting). Patients requiring a day 1 dose reduc-
tion continued to receive a reduced dose for the remainder of
the study. Patients were discontinued from the study if they
required more than 2 day 1 dose reductions, more than 42
days to recover from toxicities, or if they experienced unac-
ceptable toxicities.
Study Endpoints
The primary end point of the trial was tumor response
rate, defined as best response reported by the investigator
throughout all cycles of therapy and follow-up visits ac-
cording to Response Evaluation Criteria in Solid Tumors
criteria.18 Secondary endpoints were duration of response,
time to progression (TTP), survival time and safety. Duration
of response was defined as the time from the first objective
status assessment of complete response (CR) or partial re-
sponse (PR) until the first time of progression, or death from
any cause. TTP was defined as the time from study enroll-
ment to the first date of disease progression, and censored at
the date of death for patients who did not have documented
disease progression. Survival time was defined as the time
from study enrollment to the time of death from any cause,
and censored at the date of the last follow-up visit for patients
who were still alive. Safety was assessed by measuring the
incidence of treatment-emergent adverse events.
Statistical Methods
As response to chemotherapy is known to be markedly
different between sensitive and refractory patients, separate
analyses for each patient group were planned. Tumor re-
sponse rate was calculated as the sum of the number of
observed CRs and PRs, divided by the number of patients
qualifying for the efficacy analysis, (i.e., patients who met
enrollment criteria and received at least one dose of study
medication). Two-sided 95% CIs for response were calcu-
lated using exact binomial distribution at an alpha level of
0.05. Log-log transformation was used to calculate 95% CIs
for TTP and survival. As noted above, response duration for
responding patients was calculated from the date of CR or PR
until the first date of documented progression, or death from
any cause. TTP and overall survival were analyzed using the
Kaplan-Meier method.22 Toxicities were graded according to
Common Toxicity Criteria version 2.020 and summarized by
incidence rates. Dose-intensity was calculated as the actual
amount of drug administered in all cycles divided by the
planned dose for all cycles.
RESULTS
Patients
Simultaneous enrollment into both the sensitive and
refractory cohorts began in July 2004. As the trial progressed,
fewer than 3 responses in the first 14 qualified sensitive
patients were observed. The stopping rule was invoked and
enrollment into the sensitive cohort was halted, while the
refractory cohort completed enrollment of the planned 25
patients. Subsequently and in light of phase I data demon-
strating the tolerability of pemetrexed at a 900 mg/m2 dose,23
the protocol was amended to study this higher dose in
additional cohorts of 40 sensitive and 40 refractory patients.
The last patient completed the trial in September 2006.
In total, 143 patients signed consent for the study; 121
were assigned to treatment (56 sensitive patients, 65 refrac-
tory patients); 116 received at least one dose of study drug; 5
completed the study; 111 did not complete the study. Com-
pleting patients were defined as those who received at least
six cycles of treatment. Of 121 enrolled, 99 patients (82%)
experienced disease progression prior to completing 6 cycles.
Sensitive and refractory patients were analyzed separately at
both the 500 and 900 mg/m2 dose levels.
Of 121 enrolled patients, the numbers of males and
females were similar (60 males; 61 females). Median age
ranged from 61.7 to 67.5 years across the 4 treatment groups
and the predominant race was Caucasian (93%). The majority
of patients had ES disease at enrollment (ES, 86%; LS, 14%).
Most patients had an Eastern Cooperative Oncology Group
performance status of 0 or 1 (0/1/2: 34%/50%/17%). All
patients had received prior chemotherapy, 59% had received
prior radiation, 24% had received prior surgery, and 3% of
patients had received prior hormones or biologic therapies.
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Table 1 details baseline characteristics of the patients in the
intent-to-treat (ITT) population by treatment group.
Drug Administration
One-hundred-sixteen patients received a total of 266 cy-
cles, with a median of 2 cycles received across all the treatment
groups. Pemetrexed dose delays and reductions occurred infre-
quently, and median dose intensities of 100% were achieved
across all treatment groups. Table 2 summarizes the exposure to
study medications for treated patients during all cycles.
Antitumor Activity
No patients were observed to have a confirmed CR
during the study, and one patient had a PR in the sensitive
900 mg/m2 dosing group, for a response rate of 2.63% (95%
CI 0.07–13.81) in this group. The duration of response in this
one responding patient was 15.7 months. The overall response
rate for all patient groups was 0.9%. Approximately 16% of
patients demonstrated a best response of stable disease (SD).
The disease control rate (CR PR SD) for all patient groups
was 16.4%. Eighty-seven patients (75%) experienced progres-
sive disease. Ten patients (8.6%) had no postbaseline tumor
measurements available for response evaluation. Table 3 sum-
marizes tumor response rates in the safety population.
Figure 1 illustrates TTP in the ITT population. Median
TTP was similar across all 4 treatment groups, ranging from
1.2 to 1.5 months. The percentage of patients without pro-
gressive disease ranged from 6.8 to 25.4% across treatment
groups at the 3-month mark. At 1 year, there were no patients
without progression in the sensitive 500 mg/m2 and refractory
900 mg/m2 groups; 15% and 6.3% of patients were without
progression at 1 year in the sensitive 900 mg/m2 and refrac-
tory 500 mg/m2 groups, respectively.
Figure 2 illustrates overall survival in the ITT population.
Across the treatment groups, median survival times ranged from
2.5 to 6.1month and 1-year survival rates ranged from5.6 to 25.8%.
Toxicity
Table 4 summarizes the incidence of grade 3 and grade
4 hematologic and nonhematologic toxicities. Neutropenia
and leukopenia were the most common grade 3–4 hemato-
logic toxicities, and occurred with slightly higher incidence at
the 500 mg/m2 dose. Other serious hematologic toxicities
occurred rarely at either dosing level. Grade 3–4 nonhema-
tologic toxicities occurring in 5% or more of patients at both
dose levels were abdominal pain, asthenia, back pain, dehy-
dration, dyspnea, fatigue, and hyponatremia. Grade 2 alope-
cia occurred in 4 patients (10.5%) at the 500 mg/m2 dose, and
no patients at the 900 mg/m2 dose.
One treatment-related death occurred, involving a 71-
year-old male who developed febrile neutropenia, anemia,
and sepsis syndrome after receiving one dose of pemetrexed
TABLE 1. Patient Baseline Characteristics by Treatment
Group, Intent-to-Treat Population (n  121)
Sensitive Refractory
P 500a
n  15
P 900a
n  41
P 500a
n  25
P 900a
n  40
Gender n (%)
Female 05 (33.3) 22 (53.7) 15 (60.0) 19 (47.5)
Male 10 (66.7) 19 (46.3) 10 (40.0) 21 (52.5)
Age (yr)
Median 67.5 64.4 64.8 61.7
Minimum, maximum 51.5–82.0 43.0–81.0 45.2–85.1 35.2–82.6
ECOG performance
status n (%)
0 05 (33.3) 20 (48.9) 5 (20.0) 11 (27.5)
1 10 (66.7) 13 (31.7) 15 (60.0) 22 (55.0)
2 — (—) 08 (19.5) 05 (20.0) 07 (17.5)
Stage of disease at
enrollment n (%)
Limited 3 (20.0) 7 (17.1) 5 (20.0) 2 (5.0)
Extensive 12 (80.0) 34 (82.9) 20 (80.0) 38 (95.0)
Prior treatments n (%)
Chemotherapy 15 (100) 41 (100) 25 (100) 40 (100)
Radiotherapy 10 (66.7) 34 (82.9) 13 (52.0) 14 (35.0)
Surgery 03 (20.0) 06 (14.6) 11 (44.0) 09 (22.5)
Hormones/biological
therapy
01 (6.7) — (—) 03 (12.0) — (—)
a Pemetrexed dosing units are mg/m2.
ECOG, Eastern Cooperative Oncology Group; P, pemetrexed.
TABLE 2. Exposure to Study Drug, Safety Population (n  116)
Sensitive Refractory
P 500a
n  15
P 900a
n  38
P 500a
n  23
P 900a
n  40
Total cycles of treatment 35 89 69 73
Median no. cycles received n (range) 2.0 (1–8) 2.0 (1–7) 2.0 (1–12) 2.0 (1–5)
Patients with dose adjustments n (%) 1 (6.7) 3 (7.9) 2 (8.7) 5 (12.5)
Dose reductions 1 (6.7) — (—) 1 (4.3) 2 (05.0)
Dose delays — (—) 1 (2.6) 1 (4.3) 1 (02.5)
Dose omissions — (—) 2 (5.3) — (—) 2 (05.0)
Median dose intensity % (range) 100 (83–104) 100 (76–108) 100 (91–105) 100 (69–102)
a Pemetrexed dosing units are mg/m2.
P, pemetrexed.
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900 mg/m2. This patient had received folic acid and Vitamin
B12 for 14 days before initiating pemetrexed. The patient died
of cardiopulmonary arrest 18 days after the first pemetrexed
dose, and the death was deemed related to study treatment by
the investigator.
Acknowledging that treatment delay to allow vitamin
supplementation may be clinically undesirable in patients
with aggressive SCLC, this protocol recommended Vitamin
B12 administration 7 to 14 days before the first dose of
pemetrexed, but was amended during enrollment to permit
administration any time up until just before the start of the
first pemetrexed infusion. We performed a retrospective anal-
ysis of the incidence of serious toxicities relative to the timing
of Vitamin B12 administration. Patients who had received at
least one dose of folic acid prior to first dose of pemetrexed
were included in the analysis. Adverse events were tabulated
using the Medical Dictionary for Regulatory Activities, ver-
sion 10 (MedDRA MSSO, Reston, VA). Cycle 1 toxicity
results for patients who had received Vitamin B12 for 0 to 3,
4 to 6, and 7 or more days before first pemetrexed dose were
tabulated. Because toxicity results for either pemetrexed dose
were not significantly different, the analysis combined the
toxicities experienced during cycle 1 for both dosing levels.
Table 5 summarizes the results of this analysis.
FIGURE 1. Kaplan-Meier estimates
of time-to-progression for all treat-
ment groups.
TABLE 3. Tumor Response Rate by Treatment Group, Safety Population (n  116)
Sensitive Refractory
P 500a
n  15
P 900a
n  38
P 500a
n  23
P 900a
n  40
Complete response n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
95% CI — (—) — (—) — (—) — (—)
Partial response n (%) 0 (0.0) 1 (2.63) 0 (0.0) 0 (0.0)
95% CI — (—) (0.07–13.81) — (—) — (—)
Stable disease n (%) 3 (20.0) 5 (13.2) 5 (21.7) 5 (12.5)
95% CI (4.3–48.1) (4.4–28.1) (7.5–43.7) (4.2–26.8)
Progressive disease n (%) 11 (73.3) 29 (76.3) 16 (69.6) 31 (77.5)
95% CI (44.9–92.2) (59.8–88.6) (47.1–86.8) (61.6–89.2)
Unknown /unavailable n (%) 1 (6.7) 3 (7.9) 2 (8.7) 4 (10.0)
95% CI (0.2–32.0) (1.7–21.4) (1.1–28.0) (2.8–23.7)
Response (CRPR) n (%) 0 (0.0) 1 (2.63) 0 (0.0) 0 (0.0)
95% CI — (—) (0.07–13.81) — (—) — (—)
Patients with CR/PR/SD n (%) 3 (20.0) 6 (15.8) 5 (21.7) 5 (12.5)
Median duration of disease control months (range) 2.1 (1.3–6.3) 8.4 (1.3–20.5) 6.2 (2.6–12.5) 3.0 (1.4–3.4)
Patients with CR/PR n  1
Time to response (mo) — 4.8 — —
Response duration (mo) — 15.7 — —
a Pemetrexed dosing units are mg/m2.
CI, confidence interval; CR, complete response; NA, not applicable; P, pemetrexed; PR, partial response; SD, stable disease.
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DISCUSSION
There is currently no single best chemotherapy regimen
for relapsed SCLC, and few advances in treatment have been
made over the last two decades. The current study aimed to
evaluate the efficacy of pemetrexed as a new agent in this
disease, as measured by tumor response rate.
Disappointingly, we observed a PR in just one sensitive
patient treated with the 900 mg/m2 dose, for a response rate of
2.63% in this group and an overall trial response rate of 0.9%.
Across all treatment groups, 16% of patients had a best response
of SD, for an overall disease control rate of 16.4%. For all
patients, median times to progression were short (less than 2
months) and median survival was 6 months at best, in sensitive
patients. These results suggest that pemetrexed as a single agent
is minimally effective in the treatment of relapsed SCLC. Our
results are similar to those obtained in one earlier trial conducted
by the Hoosier Oncology Group, in which sensitive and refrac-
tory SCLC (or poorly-differentiated neuroendocrine cancer) pa-
tients who had received one or 2 lines of prior treatment were
given pemetrexed 500 mg/m2 intravenously every 21 days for
up to 6 cycles. In each of the trial arms, only one PR and one SD
were confirmed, which was insufficient to continue to the next
FIGURE 2. Kaplan-Meier estimates
of overall survival for all treatment
groups.
TABLE 4. Toxicity Summary by Pemetrexed Dose Level
P 500a
n  38
n (%)
P 900a
n  78
n (%)
Toxicity Grade 3 Grade 4 Grade 5 Grade 3 Grade 4 Grade 5
Hematologic
Neutropenia 3 (7.9) 3 (7.9) 0 (0.0) 7 (9.0) 0 (0.0) 0 (0.0)
Febrile neutropenia 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0)
Leukopenia 4 (10.5) 0 (0.0) 0 (0.0) 6 (7.7) 0 (0.0) 0 (0.0)
Thrombocytopenia 1 (2.6) 0 (0.0) 0 (0.0) 2 (2.6) 1 (1.3) 1 (1.3)
Anemia 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.6) 0 (0.0) 0 (0.0)
Nonhematologicb
Abdominal pain 2 (5.3) 0 (0.0) 0 (0.0) 4 (5.1) 0 (0.0) 0 (0.0)
Asthenia 2 (5.3) 0 (0.0) 0 (0.0) 3 (3.8) 0 (0.0) 0 (0.0)
Back pain 0 (0.0) 0 (0.0) 0 (0.0) 4 (5.1) 1 (1.3) 0 (0.0)
Chest pain 2 (5.3) 0 (0.0) 0 (0.0) 2 (2.6) 0 (0.0) 0 (0.0)
Dehydration 0 (0.0) 0 (0.0) 0 (0.0) 7 (9.0) 0 (0.0) 0 (0.0)
Dyspnea 2 (5.3) 2 (5.3) 0 (0.0) 7 (9.0) 1 (1.3) 0 (0.0)
Fatigue 6 (15.8) 0 (0.0) 0 (0.0) 7 (9.0) 0 (0.0) 0 (0.0)
Hyponatremia 1 (2.6) 1 (2.6) 0 (0.0) 4 (5.1) 0 (0.0) 0 (0.0)
a Pemetrexed dosing units are mg/m2.
b Events occurring in 5% of patients.
P, pemetrexed.
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phase of the two-stage trial.24 The current trial experience was
similar at the 500 mg/m2 dose, and a protocol amendment
ensued to evaluate pemetrexed 900 mg/m2 in additional sensi-
tive and refractory patients. The incidence of grade 3 and grade
4 toxicities observed was low at both dose levels, and serious
toxicities did not seem to occur more frequently at the higher
TABLE 5. Cycle 1 Adverse Events by Timing of Vitamin B12 Administration
Vitamin B12 given 0–3 d before P
a Vitamin B12 given 4–6 d before P
a Vitamin B12 given >7 d before P
a
n  12
n (%)
n  18
n (%)
n  86
n (%)
Adverse events -grades 3/4/5 7 (58.3) 6 (33.3) 41 (47.7)
Adverse events–all grades 11 (91.7) 18 (100.0) 79 (91.9)
Hematologic–grades 3/4/5
Anemia 0 (0.0) 0 (0.0) 2 (2.3)
Neutropenia 2 (16.7) 1 (5.6) 6 (7.0)
Febrile neutropenia 0 (0.0) 0 (0.0) 1 (1.2)
Leukopenia 0 (0.0) 0 (0.0) 8 (9.3)
Thrombocytopenia 1 (8.3) 1 (5.6) 1 (1.2)
Hematologic–all grades
Anemia 3 (25.0) 1 (5.6) 18 (20.9)
Neutropenia 2 (16.7) 4 (22.2) 14 (16.3)
Febrile neutropenia 0 (0.0) 0 (0.0) 1 (1.2)
Leukopenia 1 (8.3) 3 (16.7) 10 (11.6)
Thrombocytopenia 2 (16.7) 1 (5.6) 7 (8.1)
Grades 3/4/5 nonhematologic events occurring
in 5% of pts
Abdominal pain 0 (0.0) 1 (5.6) 0 (0.0)
Anorexia 0 (0.0) 1 (5.6) 1 (1.2)
Agitation 1 (8.3) 0 (0.0) 0 (0.0)
Back pain 1 (8.3) 1 (5.6) 2 (2.3)
Bilirubinemia 0 (0.0) 1 (5.6) 0 (0.0)
Confusional state 1 (8.3) 0 (0.0) 0 (0.0)
Dehydration 0 (0.0) 1 (5.6) 5 (5.8)
Diarrhea 0 (0.0) 1 (5.6) 0 (0.0)
Dizziness 0 (0.0) 1 (5.6) 0 (0.0)
Dyspnea 1 (8.3) 0 (0.0) 4 (4.7)
Fatigue 0 (0.0) 1 (5.6) 5 (5.8)
Fungal infection 1 (8.3) 0 (0.0) 0 (0.0)
Muscular weakness 0 (0.0) 1 (5.6) 0 (0.0)
Nausea 0 (0.0) 1 (5.6) 1 (1.2)
Neuropathy 0 (0.0) 1 (5.6) 0 (0.0)
Neuropathy, peripheral motor 1 (8.3) 0 (0.0) 0 (0.0)
Neuropathy, peripheral sensory 1 (8.3) 0 (0.0) 0 (0.0)
Pain 1 (8.3) 0 (0.0) 0 (0.0)
Pain in extremity 0 (0.0) 1 (5.6) 0 (0.0)
Pleural effusion 1 (8.3) 0 (0.0) 0 (0.0)
Pneumonia 1 (8.3) 0 (0.0) 2 (2.3)
Pyrexia 0 (0.0) 1 (5.6) 0 (0.0)
Respiratory arrest 1 (8.3) 0 (0.0) 0 (0.0)
All grades nonhematologic events occurring
in 25% of patients
Anorexia 4 (33.3) 3 (16.7) 13 (15.1)
Fatigue 3 (25.0) 12 (66.7) 31 (36.0)
Chest pain 3 (25.0) 0 (0.0) 7 (8.1)
Constipation 3 (25.0) 4 (22.2) 10 (11.6)
Cough 3 (25.0) 3 (16.7) 9 (10.5)
Nausea 3 (25.0) 4 (22.2) 19 (22.1)
a Patients received at least one dose of folic acid prior to first pemetrexed dose of 500 or 900 mg/m2.
P, pemetrexed.
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dose. While pemetrexed was well-tolerated at the 900 mg/m2
dose, this increased dose did not seem to improve efficacy.
As a prophylactic measure to reduce pemetrexed-re-
lated hematologic and gastrointestinal toxicity, patients are
currently instructed to take folic acid 350 to 1000 g by
mouth for at least 5 of 7 days prior to first dose of pem-
etrexed, and Vitamin B12 1000 g by intramuscular injection
within the week preceding the first dose of pemetrexed. These
recommendations are based on earlier studies which showed
that severities of pemetrexed toxicities (neutropenia, diarrhea,
nausea/vomiting, mucositis, and skin rash) correlate with
elevated homocysteine and methylmalonic acid levels, which
are markers of folate and Vitamin B12 deficiency, and that a
decreased incidence of grade 3 and grade 4 toxicities oc-
curred when adequate B-vitamin repletion was assured.16,17
Interestingly, this trial did afford us an opportunity to exam-
ine the effects of a shortened lead-in time for pemetrexed
vitamin supplementation, understandably desirable in the
real-world treatment of patients with aggressive malignan-
cies. Table 5 shows cycle 1 toxicity incidence for 3 groups of
patients—those who received at least one dose of folic acid
and Vitamin B12 for 0 to 3, 4 to 6, and 7 days prior to the
first pemetrexed dose (irrespective of the pemetrexed dose
received). These results suggest no greater incidence of serious
toxicities in patients who receive pemetrexed prior to a 7-day or
greater Vitamin B12 pretreatment period. It is possible that these
findings are influenced by the fact that the trial included patients
from the United States, where intake of multivitamin supple-
ments and vitamin-fortified foods is common. Additionally, we
acknowledge that this was a retrospective analysis with small
sample sizes, and the baseline homocysteine levels of the pa-
tients were unknown. While interesting, these results are not
generalizable and further study is warranted to more specifically
address the question of adequate vitamin lead-in time.
While the efficacy results of this trial do not compel
further study of pemetrexed as a single agent in relapsed
SCLC, they do substantiate the use of a 500 mg/m2 dose for
continued study in the first-line setting. A recent randomized
phase II trial which combined pemetrexed 500 mg/m2 with
cisplatin 75 mg/m2 or carboplatin AUC 5 in previously untreated
ES-SCLC achieved median survival times of 10.4 and 7.6
months, and 1-year survival rates of 39 and 33% in the pem-
etrexed/carboplatin and pemetrexed/cisplatin arms, respectively.
High dose intensities were achieved in both treatment arms with
low rates of serious toxicities.25 These data are similar to 8- to
10-month median survival times seen with the etoposide/plati-
num doublet, and so have spawned a large, randomized, phase
III trial designed to demonstrate noninferiority of pemetrexed/
carboplatin to etoposide/carboplatin, a current standard of care
for ES-SCLC.26 The results of this trial are eagerly awaited, and
will provide further insight into the role of the pemetrexed/
platinum combination in first-line ES-SCLC.
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